ValiRx announced that Ambrose Healthcare, a UK biotech specialising in rare diseases and drug repurposing, has opted to license VAL401. The terms of the license follow the previous agreement and are valued at up to £16 million plus royalties. This development was highly anticipated by ValiRx’s shareholders, though the timing was beyond ValiRx's control; Ambrose was in the process of raising capital to support the development of VAL401. Ambrose Healthcare will initially focus on developing VAL401 ....
